External Advisory Board

Satish Jindal, PhD, CEO
Allied Minds-Bristol Life Sciences

Satish JindalDr. Satish Jindal serves as CEO of Allied-Bristol Life Sciences, LLC (ABLS) companies. Prior to ABLS, Satish served as a Vice President, Bristol-Myers Squibb (BMS) and Managing Director of Biocon-Bristol-Myers Squibb Research Center (BBRC) in Bangalore, India. BBRC is an affiliate of BMS with ~575 R&D people with expertise in discovery and early development of drug candidates. During his tenure at BMS, he partnered with Allied Minds and BMS teams to create the unique innovator model, ABLS. He has an extensive experience in forming and building biotechnology companies, including Vedantra Inc., an immunotherapy company that he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology (MIT); Verastem Inc., a NASDAQ-listed cancer stem cell company that he co-founded with researchers from the Whitehead Institute, the Broad Institute and MIT; and NeoGenesis Inc., a drug discovery company that was acquired by Schering-Plough in 2005. He was a Vice president and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts from 2005-2008 and also worked in Business Development at UCB Pharma in UK. He did his postdoctoral work at Whitehead Institute for Biomedical Research at MIT, Cambridge, MA and at McMaster University, Hamilton, Ontario, Canada, and obtained his Ph.D in Biochemistry from Punjab University-India.

Jeanne Magram, PhD
Chief Scientific Officer, Northern Biologics

Jeanne Magram Dr. Jeanne Magram is the founding Chief Scientific Officer of Northern Biologics, an innovative start-up biotechnology company focused on the development of novel therapeutic antibodies for the treatment of oncology and fibrosis. Prior to joining Northern Biologics, Dr. Magram served as the Site Head for Pfizer's Centers for Therapeutic Innovation (CTI)-NY, an innovative partnership between Pfizer and academic medical centers to accelerate the translation of innovative discoveries into differentiated new medicines to treat diseases of high unmet medical need. Prior to CTI, Dr. Magram was Vice President, Immunology & Inflammation Research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease and delivered several candidates into clinical testing. Dr. Magram was also an Associate Director of GPCR Drug Discovery at OSI Pharmaceuticals after OSI’s acquisition of Cadus Pharmaceutical’s Drug Discovery programs, and spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.

Dr. Magram completed her post-doctoral training in the laboratory of Nobel Laureate Dr. J. Michael Bishop at the University of California, San Francisco after receiving her Ph.D in Genetics and Development from Columbia University and a BA (honors) in chemistry from Rutgers University.

David McElligott, PhD
Chief Scientific Officer, Accelerator Corp.

David McElligott Dr. David McElligott joined Accelerator in March of 2012 as its Chief Scientific Officer. Previously, he served as the founding Chief Scientific Officer at Groove Biopharma, a microRNA therapeutics company, where he was responsible for leading the spin-out of the technology from Nanogen (now part of ELITech Group). Prior to founding Groove Biopharma, Dr. McElligott served as Senior Director of Biological Sciences at ICOS Corp. where he led numerous preclinical drug discovery projects in oncology, inflammation, and urology. Several of those projects led to successful IND filings and clinical development programs. Before joining ICOS in 1997, Dr. McElligott held academic appointments in the Department of Immunology at The Scripps Research Institute and The Salk Institute for Biological Sciences. Dr. McElligott received his PhD and BS in microbiology/immunology from the University of Iowa.

Brian M. Gallagher, Jr., PhD
Partner, SR One Ltd.

Brian M. Gallagher, Jr. Dr. Gallagher, Jr. is a Partner at SR One Ltd. He established the SR One Boston office in 2010 and is focused on building innovative therapeutic and life science companies. He currently represents SR One on the boards of Aileron Therapeutics, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision, and co-manages portfolio companies Spero Therapeutics and Calcimedica. He previously led the firm's investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. He has over 15 years of investing, business development, operational, and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was responsible for corporate development, operations, and post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian worked with Alantos Pharmaceuticals. There, he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. Brian began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, the editorial board of the journal Marine Drugs, as a mentor for MassBio MassCONNECT, and is a peer reviewer for numerous journals and research funding authorities. Brian received his MS and PhD in organic chemistry from The University of Michigan and his BS in chemistry from The University of Massachusetts, where he was a Shapiro scholar.

Dennis J. Purcell
Senior Managing Partner, Aisling Capital

Dennis Purcell Mr. Purcell has served as the senior managing director of Aisling Capital since February 2000 and is responsible for the management of the Partnership, which holds approximately $1.7 billion of assets under management and has invested in over seventy-five companies across three funds since its inception.

Prior to joining Aisling Capital, Mr. Purcell served as managing director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") and was a member of the Operating Committee. While at Hambrecht & Quist, he was directly involved with more than two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a managing director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell currently serves on the Board of Directors of numerous public and private companies. He is also a member of the Board of the Life Sciences Foundation, L.E.K. consulting and a special advisor to Poliwogg Holdings, Inc. He has previously served on the Boards of the Biotechnology Industry Organization, the New York Biotechnology Association, the Irvington Institute, and was a member of the Advisory Council of Harvard Medical School.

In addition to being a regular speaker and commentator on the industry, Mr. Purcell has also authored articles in Nature Biotechnology, Xconomy, and the Journal of Biolaw and Business. Mr. Purcell has participated as a judge for the New York City Bioaccelerate Program. He has also been a guest lecturer at various universities. Mr. Purcell has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell received his MBA from Harvard University and his BS in accounting from the University of Delaware.

Susan Froshauer, PhD
President & CEO, Connecticut United for Research Excellence (CURE)

Susan Froshauer Dr. Froshauer is President and CEO of Connecticut United for Research Excellence (CURE), the bioscience association of the state of Connecticut. She is an experienced scientist, mentor, entrepreneur and investor with skill at connecting academic expertise and technology with the commercial sector. Prior to joining CURE, she was director of the Technology Exchange Portal at the University of Connecticut's Office of Economic Development.

Until 2010, Dr. Froshauer served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Dr. Froshauer served as a member of Pfizer's Strategic Alliance Group where she was key to the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery. Dr. Froshauer received her PhD in microbiology and molecular genetics from Harvard University and a BA from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child's Fellow.

Stephen P. Squinto, PhD
Venture Partner, OrbiMed Advisors

Steven Squinto In January 2015 Dr. Squinto became a venture partner with OrbiMed Advisors, the world’s largest venture capital firm focused on healthcare. Prior to January 2015, Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. (www.alxn.com) and had been a Corporate Officer since August 2000. Most recently, Dr. Squinto was the Executive Vice President and Chief Global Operations Officer, a member of the Executive Steering Committee and was responsible for Global Manufacturing, Quality and Project Management. Prior to 2013 he was the Global Head of Research and Development, a position he has held since 2007 where he was responsible for Clinical Development, Medical Affairs, Regulatory Affairs, Pharmacovigilence, Drug Discovery, Translational Medicine and Portfolio Management.

Other positions he has held at Alexion include, Executive VP, Head of Research and Clinical Development from 2006-2007, Executive VP, Head of Research from 2000-2006, Senior Vice President and Chief Technology Officer from 1998 to 2000, Vice President of Research, Molecular Sciences, from 1994 to 1998, Senior Director of Molecular Sciences from 1993 to 1994 and Director of Molecular Development from 1992 to 1993. Prior to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc., including serving as the Co-Director of the Drug Discovery Group. Dr. Squinto was among the founding scientists hired at Regeneron in 1989. Prior to his position at Regeneron, Dr. Squinto held a joint appointment as an Assistant Professor of Biochemistry and Molecular Biology and Neuroscience at both Tulane University Medical School and Louisiana State University Medical Center from 1986 to 1989.

Dr. Squinto is a recipient of numerous honors and awards from academic and professional organizations and his scientific work has led to over 70 scientific publications and over 40 patents in the fields of molecular biology, biochemistry, biotechnology and neuroscience. He currently serves on the boards of several private companies as well as several charitable organizations. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Francois Nader, MD, MBA
Chairman, Acceleron Pharma
Former CEO, NPS Pharma

Francois Nader Francois Nader, MD, is currently the chairman of Acceleron Pharma and a leading value builder in the biopharma industry. He was President, Chief Executive Officer and Executive Director of NPS Pharma from 2008 to 2015, when the company was acquired by Shire for $5.2B. During his tenure as CEO Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. He was recognized as the Ernst and Young National Life Science Entrepreneur of the Year® in 2013. Dr. Nader currently serves as chairman of the board of directors of Acceleron Pharma (NASDAQ: XLRN) and board director of Advanced Accelerator Applications (NASDAQ: AAAP), Clementia Pharmaceuticals and ArRETT Neuroscience.

Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.

Dr. Nader is a recognized leader in industry and philanthropic organizations. He is the President of the Jesra Foundation, a trustee of the New Jersey Chamber of Commerce and sits on the Advisory Board of the Open Future Institute. He is the past chairman of BioNJ, New Jersey’s biotechnology trade organization and has served on the board of the Biotechnology Industry Organization (BIO), the national industry body, NPS Pharma (NASDAQ: NPSP), Baxalta (NYSE: BXLT), Trevena (NASDAQ: TRVN) and Noven (NASDAQ: NOVN).

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and his Physician Executive MBA from the University of Tennessee.